AN2 Therapeutics (ANTX)
(Delayed Data from NSDQ)
$2.27 USD
0.00 (0.00%)
Updated May 17, 2024 04:00 PM ET
After-Market: $2.26 -0.01 (-0.44%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANTX 2.27 0.00(0.00%)
Will ANTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ANTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANTX
Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why
AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why
ANTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Beat the Market the Zacks Way: Novo Nordisk, Lifeway Foods, Casey's in Focus
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
Other News for ANTX
AN2 Therapeutics price target lowered by $5 at Evercore ISI, here's why
AN2 Therapeutics reports Q1 results
Oppenheimer Sticks to Their Hold Rating for AN2 Therapeutics, Inc. (ANTX)
Analysts Are Bullish on These Healthcare Stocks: AN2 Therapeutics, Inc. (ANTX), Heron Therapeutics (HRTX)
TD Cowen Remains a Buy on AN2 Therapeutics, Inc. (ANTX)